Working to invent novel therapies that will allow us live longer, healthier lives.
Lyfspn is currently planning to carry out a pilot study of our lead longevity promoting therapy candidate, a novel apheresis-based treatment.
Apheresis is an existing therapeutic modality which plays an important role in the management of many diseases including more than 50 autoimmune disorders, a number of rare neurologic conditions, and Alzheimer's disease.
Apheresis is emerging as a prevention and therapy for other age related medical conditions.
Visit website: https://www.lyfspn.com/
People at Lyfspn
Lyfspn recruiting in USA for plasmapheresis trial using 5% human albumin
Longevity Technology - 08-Jun-2022
No mention of the Conboys, but it looks like it's based on their plasma dilution researchRead more...